Verrica Pharmaceuticals is a dermatology therapeutics company developing medications for skin diseases requiring medical intervention. Co.'s product pipeline consists of: VP-102, which is a propriety drug-device combination that contains a good manufacturing practices-controlled formulation of cantharidin which is being developed for potential use in treating molluscum contagiosum, external genital warts and common warts; VP-315, which is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma; and VP-103, which is a cantharidin based drug device combination for the potential treatment of plantar warts. The VRCA average annual return since 2018 is shown above.
The Average Annual Return on the VRCA average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether VRCA average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VRCA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|